Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Alessandro Di Minno,Roberta Lupoli,Ilenia Calcaterra,Paolo Poggio,Francesco Forte,Gaia Spadarella,Pasquale Ambrosino,Gabriella Iannuzzo,Matteo Nicola Dario Di Minno
DOI: https://doi.org/10.1161/JAHA.119.016262
IF: 6.106
2020-07-23
Journal of the American Heart Association
Abstract:Background Bempedoic acid (BA) is a novel lipid‐lowering drug. We performed a systematic review and meta‐analysis on efficacy and safety of BA compared with standard treatment in patients with hypercholesterolemia. Methods and Results Studies were systematically searched in the PubMed, Web of Science, Scopus, and EMBASE databases. Efficacy outcome was represented by percentage changes (mean difference [MD] with pertinent 95% CIs) in total cholesterol, low‐density lipoprotein cholesterol, triglycerides, high‐density lipoprotein cholesterol, apolipoprotein B, non–high‐density lipoprotein cholesterol, and hs‐CRP (high‐sensitivity C‐reactive protein) in BA patients and controls. Seven studies were included (2767 BA‐treated patients and 1469 controls), showing a more significant reduction in low‐density lipoprotein cholesterol (MD, −17.5%; 95% CI, −22.9% to −12.0%), total cholesterol (MD, −10.9%; 95% CI, −13.3% to −8.5%), non–high‐density lipoprotein cholesterol (MD, −12.3%; 95% CI, −15.3% to −9.20%), apolipoprotein B (MD, −10.6%; 95% CI, −13.2% to −8.02%), and hs‐CRP (MD, −13.2%; 95% CI, −16.7% to −9.79%) in BA‐treated patients compared with controls. Results were confirmed when separately analyzing studies on patients with high cardiovascular risk, studies on statin‐intolerant patients, and studies on patients with hypercholesterolemia on maximally tolerated lipid‐lowering therapy. BA‐treated subjects reported a higher rate of treatment discontinuation caused by adverse effects, of gout flare, and of increase in uric acid compared with controls. On the other hand, BA‐treated patients showed a lower incidence of new‐onset diabetes mellitus than controls. Conclusions BA is associated with a significant reduction in low‐density lipoprotein cholesterol, total cholesterol, non–high‐density lipoprotein cholesterol, apolipoprotein B, and hs‐CRP compared with standard treatment. Documented efficacy is accompanied by an acceptable safety profile. Nonstandard Abbreviations and Acronyms Apo Bapolipoprotein B BA bempedoic acid HDL‐C high‐density lipoprotein cholesterol hs‐CRP high‐sensitivity C‐reactive protein LDL‐C low‐density lipoprotein cholesterol MD mean difference OR odds ratio RCT randomized controlled trial TC total cholesterol Clinical Perspective What Is New? Bempedoic acid is a safe and effective lipid‐lowering agent for the treatment of hypercholesterolemia, associated with a significant reduction in total cholesterol, low‐density lipoprotein cholesterol, non–high‐density lipoprotein cholesterol, apolipoprotein B, and hs‐CRP (high‐sensitivity C‐reactive protein). Bempedoic acid is a valuable treatment option (1) for patients with statin intolerance, not able to receive an adequate lipid‐lowering treatment; and (2) for patients with high cardiovascular risk, not reaching desired target of low‐density lipoprotein cholesterol despite a maximally tolerated lipid‐lowering treatment, including both statin and ezetimibe. What Are the Clinical Implications? Although data are currently lacking, a treatment with bempedoic acid on top of maximally tolerated lipid‐lowering treatment might reduce the need of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors. Several studies emphasize the role of high levels of low‐density lipoprotein cholesterol (LDL‐C) as the main causative factor in atherosclerosis development. 1 , 2 Among patients with hypercholesterolemia, those with high levels of LDL‐C exhibit increased prevalence of subclinical atherosclerosis and a more rapid atherosclerosis progression, thus leading to a significantly higher cardiovascular risk 1 and related dis -Abstract Truncated-
cardiac & cardiovascular systems